Genome-edited crops are seen as a bridge between conventional breeding and GM technology. Critically evaluate India's 2025 release of genome-edited rice varieties.

Genome editing (CRISPR-Cas, SDN-1/SDN-2) changes a plant's own genes without inserting foreign DNA. It is faster than conventional breeding, but the result is not transgenic like GM crops. In May 2025, ICAR released DRR Dhan 100 (Kamala) and Pusa DST Rice 1, India's first genome-edited rice [2]. The idea is scientifically sound, but the release came before the evidence and the oversight were in place.

Merits: why the "bridge" claim holds

• Climate urgency: without adaptation, ICAR–NICRA projects that rainfed rice yields will fall 20% by 2050 and 47% by 2080 [1]. Editing proven elite varieties such as Samba Mahsuri, the parent of Kamala, adds stress tolerance quickly.
• Precision without transgenes: the varieties carry no foreign DNA [2]. In 2022, MoEFCC exempted SDN-1/SDN-2 plants from Rules 7–11 of the 1989 Rules [3], which makes regulation clearer and cheaper.
• Targeted traits: the claimed traits are drought and salinity tolerance and earlier maturity, which saves irrigation water [2].
• Public-sector lead: the varieties were developed by ICAR, not by corporations. They add to the 199 extreme-climate-resilient varieties bred conventionally in 2014–24 [1].

Concerns: where the release falls short

• Contested evidence: independent analyses of ICAR's own trial data question the claimed yield and early-maturity gains. ICAR replies that only data from the target zones count. When the main benefit is disputed, farmers have less reason to trust the seed.
• Self-regulation: under the 2022 SOPs, the developer's own Institutional Biosafety Committee reviews the crop and RCGM only records the decision [3]. GEAC is bypassed, so the developer is in effect checking itself.
• IPR and seed sovereignty: the core CRISPR-Cas9 patents belong to the Broad Institute and Corteva, and even IRRI needed a licence to use them [4]. This creates risks of royalties and dependence.
• Adoption gap: official records count varieties released, not area sown [1]. Seed multiplication and extension services decide whether smallholders ever receive them.

The 2025 release is a real technological step, but it was made before independent proof of benefit and independent biosafety review. The way forward is to:

• publish the full multi-location trial data;
• set up an independent biosafety assessment body;
• secure freedom-to-operate licences;
• plan seed supply chains at the time of release.

With these in place, genome editing can bridge breeding and GM technology and help meet SDG 2 (Zero Hunger) and SDG 13 (Climate Action).